Q1 · MEDICINE
Article
Author: Willard, Francis S. ; Briere, Daniel A. ; Yumibe, Nathan ; Sloop, Kyle W. ; Minguez, José Miguel ; Mateo, Ana I. ; Bueno, Ana B. ; Showalter, Aaron D. ; Corkins, Christopher M. ; Castaño, Ana M. ; Cumming, Graham R. ; Wainscott, David B. ; Cardona, Guemalli R. ; Chen, Qi ; Ma, Wenzhen ; Jiménez, Alma ; Agejas, Javier ; Stutsman, Cynthia ; Zink, Richard W.
The identification of LSN3318839, a positive allosteric modulator of the glucagon-like peptide-1 receptor (GLP-1R), is described. LSN3318839 increases the potency and efficacy of the weak metabolite GLP-1(9-36)NH2 to become a full agonist at the GLP-1R and modestly potentiates the activity of the highly potent full-length ligand, GLP-1(7-36)NH2. LSN3318839 preferentially enhances G protein-coupled signaling by the GLP-1R over β-arrestin recruitment. Ex vivo experiments show that the combination of GLP-1(9-36)NH2 and LSN3318839 produces glucose-dependent insulin secretion similar to that of GLP-1(7-36)NH2. Under nutrient-stimulated conditions that release GLP-1, LSN3318839 demonstrates robust glucose lowering in animal models alone or in treatment combination with sitagliptin. From a therapeutic perspective, the biological properties of LSN3318839 support the concept that GLP-1R potentiation is sufficient for reducing hyperglycemia.